Did You Know...
...that the inventor of the electric motor was a blacksmith named Thomas Davenport? Described as "a brilliantly unsuccessful inventor", Davenport invented the first rotary electric motor. In 1836 he headed out -- on foot -- from his Vermont home to file a patent application at the Patent Office in Washington, D.C. By the time he got there, he had squandered away his money and couldn't afford the $30 filing fee so he turned around and went home. When he later mailed in his application with money he'd raised, the Patent office was destroyed in a fire. He did finally get credit for his invention on Feb. 5, 1837.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8080525 | Peptide compositions and their use against the hepatitis C virus Novel peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B havi... | 12/20/2011 |
| 7393831 | Peptide compositions and their use against HCV The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N | 07/01/2008 |
| 7361355 | Mutant forms of cholera holotoxin as an adjuvant Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wi... | 04/22/2008 |
| 7341728 | Internalisation of virus into cells A chimeric transmembrane protein which promotes viral entry into cells comprises: (i) an extracellular domain capable of binding a virus; and (ii) an intracellular internalisation signal. ... | 03/11/2008 |
| 7314919 | Human recombinant antibody against the hepatitis C (HCV) non structural NS3 protein nucleic acid and uses thereof An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof. ... | 01/01/2008 |
| RE39586 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVSAG) Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention and treatme... | 04/24/2007 |
| 7195765 | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 ... | 03/27/2007 |
| 7135170 | Methods for treating viral infection using IL-28 and IL-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus.... | 11/14/2006 |
| 7101551 | Remedies for hepatitis C The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-vi... | 09/05/2006 |
| 6951646 | Anti hepatitis C virus antibody and uses thereof Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-describe... | 10/04/2005 |
| 6814964 | Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids A supramolecule has a first supramolecular component including a first effector molecule covalently joined to a first nucleic acid, and a second supramolecular component including a second effector molecule covalently joined to a second nucleic acid, wherein the sec... | 11/09/2004 |
| 6787137 | Campylobacter vaccine The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonisation in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of... | 09/07/2004 |
| 6682909 | Immunogenic composition of hepatitis C and methods of use thereof The present invention provides truncated HCV E2 polypepides. The invention HCV E2 polypeptides lack the HVR1 region that provides immune protection against HCV. The present invention also provides immunogenic compositions of such polypeptides and the meth... | 01/27/2004 |
| 6610295 | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying betwee... | 08/26/2003 |
| 6410009 | Pharmaceutical composition for treating hepatitis B virus (HBV) infection The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hep... | 06/25/2002 |
| 6379699 | Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. One effector molecule is a binding molecule such as an antibody or Fc receptor that binds to a molecular target such as a virus or anti... | 04/30/2002 |
| 6372216 | Method of producing specific immunoglobin to block HCV infection A drug which protects individuals against hepatitis C virus (HCV) is made of HCV hyperimmune globulins, which guarantee a substantial hyperimmunity against HCV thanks to a substantial hyperconcentration of virus C neutralizing antibodies. This hyperconcen... | 04/16/2002 |
| 6180099 | Method of using immunoglobulin and fiber-containing compositions for human health A composition for restoring and maintaining gastrointestinal health comprises 40-60% by weight of an immunoglobulin composition comprising concentrated immunologically active immunoglobulins and 40-60% by weight of soluble dietary fiber selected from inul... | 01/30/2001 |
| 6171782 | Antibody compositions to HCV and uses thereof A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infe... | 01/09/2001 |
| 6146629 | Human monoclonal antibody against Hepatitis B virus surface antigen (HBVsAg) Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention ... | 11/14/2000 |
| 6099840 | Hepatitis B vaccine A variant HBsAg protein of fragment thereof displaying the antigenicity of Hepatitis B virus surface antigen is disclosed, in which the variant protein or fragment thereof (vHBsAg) comprises a modified a determinant in which there is an amino acid other t... | 08/08/2000 |
| 6030616 | Hepatitis B escape mutant specific binding molecules Molecules which are capable of specifically binding to a hepatitis B escape mutant antigenic determinant include monoclonal antibodies secreted by the cell line SMH HBs 145/G/R/I (ECACC 92122312). SMH HBs 145/R/I (ECACC 93052626). SMH HBs 145/G/II (ECACC ... | 02/29/2000 |
| 6004561 | High level expression of polypeptide that contains modified preS1 region of hepatitis B virus large antigen The present invention relates to methods of producing recombinant molecules including the nucleotide sequence for the structure of the preS1 region of the surface glycoprotein of the hepatitis B virus, and to compositions of the molecules. Compositions of... | 12/21/1999 |
| 5997861 | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. One effector molecule is a binding molecule such as an antibody or Fc receptor that binds to a molecular target such as a virus or anti... | 12/07/1999 |
| 5919454 | Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications This invention relates to human or murine monoclonal antibodies specific for a peptide sequence of HCV E1, fragments of said monoclonal antibodies, hybridomas producing said monoclonal antibodies, in vitro diagnostic methods for detecting HCV E1-specific ... | 07/06/1999 |
| 5851758 | Cytopathic replication of hepatitis C virus in a new cell line We have cloned human lymphoid cell lines that are susceptible to hepatitis C virus (HCV) infection, and in which infection with HCV results in the development of cytopathic effects, including cell degeneration, induction of cell syncytia and cell death, a... | 12/22/1998 |
| 5681695 | Method for increasing specificity in competitive immunoassays The invention is an improved immunoassay and method for detection of antibody to hepatitis B core antigen (anti-HBc). The improved assay comprises the addition of a reducing agent to decrease the number of false positive reactions in the assay.... | 10/28/1997 |
| 5648077 | Treatment of patients infected with hepatitis B virus with a human monoclonal antibody Monoclonal antibodies effective for the diagnosis and treatment of hepatitis B have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with blood cells of a patient immunized with hepatitis B vaccine. The chimeric h... | 07/15/1997 |
| 5531989 | Immunoglobulin and fiber-containing composition for human gastrointestinal health A composition for restoring and maintaining gastrointestinal health comprises 40-60% by weight of an immunoglobulin composition comprising concentrated immunologically active immunoglobulins and 40-60% by weight of soluble dietary fiber selected from inul... | 07/02/1996 |
| 5098704 | Hepatitis surface antigen particle vaccine Vaccines are provided produced by hybrid DNA technology for Hepatitis B virus comprising Hepatitis B surface antigen particles containing a human polyalbumin binding site receptor. Constructs are provided for expression of the vaccine protein, which upon ... | 03/24/1992 |
| 4849508 | Pasteurization of immunoglobulin solutions Pasteurization of immunoglobulin solutions to inactivate viruses without significantly altering the IgG molecules or their physiological activities is obtained with minimal aggregation in the absence of any stabilizer by heating this solution to mildly-el... | 07/18/1989 |
| 4701421 | Determination of protecting anti-HBV immunoglobulins A novel method for the determination of protecting anti-HBV immunoglobulins is based on the use of two different HBsAg reagents: one insolubilized and having the antigenic type AX and one labelled and having the antigenic type AY, wherein A represents the... | 10/20/1987 |
| 4542016 | Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use A new vaccine against viral NANB hepatitis containing NANBs antigen in a physiologically acceptable medium. The vaccine is prepared by selecting serums or plasmas in which the presence of NANBs antigens has been identified and thereafter purifying the sai... | 09/17/1985 |
| 4346073 | Hepatitis B immune globulin used to inactivate hepatitis B virus in injectable biological products The utilization of hepatitis B immune globulin as a preparation for preventing transmission of the hepatitis B virus (HBV) by injectable biologics, by incubation of the injectable biologics and hepatitis B immune globulin together in vitro prior to admini... | 08/24/1982 |
| 4296024 | Human immune serum globulin with high hepatitis A antibody titer An immune adherence hemagglutination assay for detection of hepatitis A antigen or antibody. Plasma having known high titer of hepatitis A antibody, and gamma globulin having known high titer of hepatitis A antibody.... | 10/20/1981 |
| 4174388 | Method for preparing hepatitis B immune globulin Hepatitis B immune globulin is prepared from individuals who exhibit an increase in hepatitis B surface antibody of at least 2,000 PHA units/ml following immunization with hepatitis B surface antigen.... | 11/13/1979 |
| 4087519 | Medicament for the treatment of hepatitis and/or acute or chronic infections due to the virus of hepatitis B This invention relates to a medicament which contains a gamma-globulin preparation containing anti-e antibodies. This medicament can be used for eliminating or reducing the infectiousness of biological liquids containing antigen-e or the virus of hepatiti... | 05/02/1978 |
| 4021540 | Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material A method for producing a novel immunizing agent is described. The immunizing agent is anti-HBs gamma globulin essentially free of fibrinogen, plasminogen, 19 S globulin and lipids found to be effective in immunizing against hepatitis B virus di... | 05/03/1977 |
